A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment

Summary

The purpose of this study is to measure how much of the drug gets into the bloodstream and how long it takes the body to remove it when given to participants with hepatic (liver) impairment compared to participants with normal hepatic function. Information about any side effects that may occur will also be collected. This study will last approximately 28 days, not including screening.

Timeline

Start

2013-04

Primary completion

2013-10

Completion

2013-10

Drugs

Indications